Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SALOX plus bevacizumab as first-line treatment in advanced colorectal cancer
ChiCTR2100053431Phase 2Recruiting
- Sponsor
- Fujian Medical University Union Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of raltitrexed, oxaliplatin and bevacizumab in colorectal cancer (CRC), sponsored by Fujian Medical University Union Hospital. Primary endpoint: Objective Response Rate. Started Dec 2021; status: recruiting.
02
Drugs
raltitrexedoxaliplatinbevacizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100053431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053431.